A synthetic peptide for use as a blocking control in assays to test for specificity of GRM7 antibody, Alternative Names: GRM7 control peptide, GRM7 antibody Blocking Peptide, Anti-GRM7 Blocking Peptide, glutamate receptor, metabotropic 7 Blocking Peptide, FLJ40498 Blocking Peptide, GLUR7 Blocking Peptide, GPRC1G Blocking Peptide, MGLU7 Blocking Peptide, MGLUR7 Blocking Peptide, GRM7, GRM-7, GRM 7, GRM-7 Blocking Peptide, GRM 7 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
GRM7
(Glutamate Receptor, Metabotropic 7 (GRM7))
Hintergrund
L-glutamate is the major excitatory neurotransmitter in the central nervous system, and it activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors that have been divided into three groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5, and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3, while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Multiple transcript variants encoding different isoforms have been found for this gene.